• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Salisbury Bancorp

Salisbury Bancorp

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

    Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Leukemia (APL)

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.